These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 34370565)
1. Evaluating Locally Developed Interventions to Promote PrEP Among Racially/Ethnically Diverse Transgender Women in the United States: A Unique CDC Initiative. Rhodes SD; Kuhns LM; Alexander J; Alonzo J; Bessler PA; Courtenay-Quirk C; Denson DJ; Evans K; Galindo CA; Garofalo R; Gelaude DJ; Hotton AL; Johnson AK; Mann-Jackson L; Muldoon A; Ortiz R; Paul JL; Perloff J; Pleasant K; Reboussin BA; Refugio Aviles L; Song EY; Tanner AE; Trent S AIDS Educ Prev; 2021 Aug; 33(4):345-360. PubMed ID: 34370565 [TBL] [Abstract][Full Text] [Related]
2. Multilevel Barriers to HIV PrEP Uptake and Adherence Among Black and Hispanic/Latinx Transgender Women in Southern California. Ogunbajo A; Storholm ED; Ober AJ; Bogart LM; Reback CJ; Flynn R; Lyman P; Morris S AIDS Behav; 2021 Jul; 25(7):2301-2315. PubMed ID: 33515132 [TBL] [Abstract][Full Text] [Related]
3. Preexposure Prophylaxis Uptake Among Spanish-Speaking Transgender Women: A Randomized Controlled Trial in North and South Carolina, 2019-2022. Rhodes SD; Alonzo J; Mann-Jackson L; Aviles LR; Tanner AE; Galindo CA; Bessler PA; Courtenay-Quirk C; Garcia M; Sucaldito AD; Smart BD; Goldenberg T; Reboussin BA Am J Public Health; 2024 Jan; 114(1):68-78. PubMed ID: 38091558 [No Abstract] [Full Text] [Related]
4. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States. Malone J; Reisner SL; Cooney EE; Poteat T; Cannon CM; Schneider JS; Radix A; Mayer KH; Haw JS; Althoff KN; Wawrzyniak AJ; Beyrer C; Wirtz AL; J Acquir Immune Defic Syndr; 2021 Sep; 88(1):10-18. PubMed ID: 34397742 [TBL] [Abstract][Full Text] [Related]
5. HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States. Sevelius JM; Poteat T; Luhur WE; Reisner SL; Meyer IH J Acquir Immune Defic Syndr; 2020 Aug; 84(5):437-442. PubMed ID: 32692101 [TBL] [Abstract][Full Text] [Related]
6. "Some of us, we don't know where we're going to be tomorrow." Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. Cahill SR; Keatley J; Wade Taylor S; Sevelius J; Elsesser SA; Geffen SR; Wang T; Mayer KH AIDS Care; 2020 May; 32(5):585-593. PubMed ID: 31482726 [TBL] [Abstract][Full Text] [Related]
7. Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States. Chandler CJ; Creasy SL; Adams BJ; Eaton LA; Bukowski LA; Egan JE; Friedman MR; Stall RD; Whitfield DL AIDS Behav; 2021 Sep; 25(9):2929-2940. PubMed ID: 33606134 [TBL] [Abstract][Full Text] [Related]
8. HIV Pre-exposure Prophylaxis Indication and Readiness Among HIV-Uninfected Transgender Women in Ho Chi Minh City, Vietnam. Oldenburg CE; Le B; Toan T; Thien DD; Huyen HT; Friedman MR; Stall R; Colby D AIDS Behav; 2016 Dec; 20(Suppl 3):365-370. PubMed ID: 27435073 [TBL] [Abstract][Full Text] [Related]
9. Adapting a Group-Level PrEP Promotion Intervention Trial for Transgender Latinas During the COVID-19 Pandemic. Rhodes SD; Tanner AE; Mann-Jackson L; Alonzo J; Refugio Aviles L; Galindo CA; Bessler PA; Courtenay-Quirk C; Smart BD; Garcia M; Goldenberg T; Sucaldito AD; Reboussin BA AIDS Educ Prev; 2022 Dec; 34(6):481-495. PubMed ID: 36454131 [TBL] [Abstract][Full Text] [Related]
10. The ethical imperative to reduce HIV stigma through community-engaged, status-neutral interventions designed with and for transgender women of colour in the United States. Gamarel KE; Rebchook G; McCree BM; Jadwin-Cakmak L; Connolly M; Reyes LA; Sevelius JM J Int AIDS Soc; 2022 Jul; 25 Suppl 1(Suppl 1):e25907. PubMed ID: 35818894 [TBL] [Abstract][Full Text] [Related]
11. Dismantling Barriers and Transforming the Future of Pre-Exposure Prophylaxis Uptake in Young Black and Latinx Sexual Minority Men and Transgender Women. Shorrock F; Alvarenga A; Hailey-Fair K; Vickroy W; Cos T; Kwait J; Trexler C; Wirtz AL; Galai N; Beyrer C; Celentano D; Arrington-Sanders R AIDS Patient Care STDS; 2022 May; 36(5):194-203. PubMed ID: 35507322 [TBL] [Abstract][Full Text] [Related]
12. Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities. Jones MD; Jones K; Almirol E; Payne G; Graves B; Schneider JA; Rijos D; Zawitz C; Zimmerman R; Seal DW; Brewer R; DrPH RB AIDS Behav; 2023 Apr; 27(4):1304-1313. PubMed ID: 36264406 [TBL] [Abstract][Full Text] [Related]
13. PrEP Uptake and Discontinuation Among a U.S. National Sample of Transgender Men and Women. Zarwell M; John SA; Westmoreland D; Mirzayi C; Pantalone DW; Golub S; Nash D; Grov C AIDS Behav; 2021 Apr; 25(4):1063-1071. PubMed ID: 33057893 [TBL] [Abstract][Full Text] [Related]
14. Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection - National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019-2020. Morris E; Teplinskaya A; Olansky E; Rinderle JK; Chapin-Bardales J; MMWR Suppl; 2024 Jan; 73(1):9-20. PubMed ID: 38261546 [TBL] [Abstract][Full Text] [Related]
15. Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs). Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman SG; Footer KHA; D'Aquila RT; Carballo-Diéguez A; Hope TJ AIDS Behav; 2020 May; 24(5):1452-1462. PubMed ID: 31654172 [TBL] [Abstract][Full Text] [Related]
16. Gender-Based Violence and Post-traumatic Stress Disorder Symptoms Predict HIV PrEP Uptake and Persistence Failure Among Transgender and Non-binary Persons Participating in a PrEP Demonstration Project in Southern California. Storholm ED; Huang W; Ogunbajo A; Horvath KJ; Reback CJ; Blumenthal J; Moore DJ; Flynn RP; Bolan RK; Corado KC; Morris SR AIDS Behav; 2023 Feb; 27(2):745-759. PubMed ID: 36053404 [TBL] [Abstract][Full Text] [Related]
17. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam. Doan AH; Vu CMH; Nguyen TT; Green KE; Phan HTT; Janamnuaysook R; Vu BN; Le TM; Do KQ; Tran TT; Ngo TM; Basu L; Tran LK; Humeau Z J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25996. PubMed ID: 36225133 [TBL] [Abstract][Full Text] [Related]
18. Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies. Wilson EC; Turner CM; Arayasirikul S; Lightfoot M; Scheer S; Raymond HF; Liu A J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25539. PubMed ID: 32602642 [TBL] [Abstract][Full Text] [Related]
19. High risk and low uptake of pre-exposure prophylaxis to prevent HIV acquisition in a national online sample of transgender men who have sex with men in the United States. Reisner SL; Moore CS; Asquith A; Pardee DJ; Sarvet A; Mayer G; Mayer KH J Int AIDS Soc; 2019 Sep; 22(9):e25391. PubMed ID: 31536171 [TBL] [Abstract][Full Text] [Related]
20. HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals. Poteat TC; Radix A Drugs; 2020 Jul; 80(10):965-972. PubMed ID: 32451925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]